Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients.

BACKGROUND AND AIM

Sarcopenia has received much attention as a poor prognostic factor in various fields, and has also been reported to worsen prognosis in patients with hepatocellular carcinoma (HCC) treated with sorafenib or lenvatinib (LEN). Atezolizumab/bevacizumab (ATZ/BEV) is recommended as first-line drug therapy for unresectable-HCC, but the effect of sarcopenia on patients treated with ATZ/BEV is unknown.

METHODS

We enrolled 98 patients treated with ATZ/BEV or LEN. Computed tomography performed before the initiation of drug therapy was used to diagnose sarcopenia in accordance with the criteria proposed by the Japanese Society of Hepatology. Patients were divided into two groups based on the presence or absence of sarcopenia in each regimen, and patient characteristics, adverse events, and prognosis were compared.

RESULTS

In ATZ/BEV therapy, 57.1% of patients had sarcopenia. The sarcopenia group had significantly more women ( = 0.0125) and more macroscopic vascular invasion ( = 0.0270). Sarcopenia had no significant effect on progression-free survival (PFS) and overall survival (OS). In LEN therapy, 63.4% of patients had sarcopenia. The sarcopenia group was significantly older ( = 0.0064) and had a higher number of women ( = 0.0003), a higher neutrophil-lymphocyte ratio ( = 0.0222), worse albumin-bilirubin grade ( = 0.0087), and worse best response ( = 0.0255). PFS ( = 0.0091) and OS ( = 0.0006) were worse in the sarcopenia group. In multivariate analysis, age ( = 0.0362), lymphocyte-monocyte ratio ( = 0.0365), and sarcopenia ( = 0.0268) were independent prognostic factors for OS.

CONCLUSION

In ATZ/BEV therapy, sarcopenia does not determine prognosis, and therapeutic efficacy can be expected even in cases of sarcopenia.